CTOs on the Move

Medical Resources Network

www.medres.net

 
Medical Resources Network is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.medres.net
  • 10725 SW Barbur Blvd Ste 200
    Portland, OR USA 97219
  • Phone: 503.452.1748

Executives

Name Title Contact Details

Similar Companies

Women’s Care

Womens Care is a womens healthcare group that provides comprehensive patient care in obstetrics, gynecology, gynecologic oncology, urogynecology, gynecologic pathology, and breast surgery, genetic counseling, maternal fetal medicine, laboratory servi...

T1D Exchange

T1D Exchange, a nonprofit organization, is a dynamic, multi-purpose, real-world patient data platform designed to accelerate all aspects of drug and device development. T1D Exchange has established a unique model to speed better treatments, therapies and research for type 1 diabetes (T1D). The Exchange consists of an integrated Clinic Network of 65+ clinics across the U.S., a Clinic Registry of 26,000 well-characterized patients, a Biorepository, and Glu, an online community with mobile capabilities for people touched by type 1 diabetes. The T1D Exchange fosters faster and more fluid information transfer and sharing among diabetes patients, physicians, researchers, and pharma, medical device, education, and outreach organizations.

CSI Medical Education

CSI Medical Education is a Madison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Consultants Network

Medical Consultants Network is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avaxia Biologics

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.